Overview

Lorbriqua (Lorlatinib) is a targeted therapy used for the treatment of certain types of lung cancer. It is specifically indicated for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to other ALK inhibitors.

Benefits

• Targets ALK mutations effectively, providing a tailored approach to treatment.
• May help improve overall survival rates in patients with advanced ALK-positive NSCLC.
• Can penetrate the blood-brain barrier, potentially addressing brain metastases.
• Administered orally, offering convenience for patients.

Dosage

The recommended dosage of Lorbriqua is 100 mg taken orally once daily. It can be taken with or without food. Patients should follow their healthcare provider's instructions regarding dosage adjustments and treatment duration.

Side Effects

Common side effects of Lorbriqua may include:

• Fatigue
• Nausea
• Diarrhea
• Peripheral neuropathy
• Elevated cholesterol levels

Patients should report any severe or persistent side effects to their healthcare provider immediately.

FAQs

What is Lorbriqua used for?

Lorbriqua is used to treat ALK-positive non-small cell lung cancer in patients who have previously undergone other treatments.

How should Lorbriqua be taken?

Lorbriqua should be taken orally once daily, with or without food, as directed by a healthcare professional.

Are there any interactions with Lorbriqua?

Yes, Lorbriqua may interact with certain medications. It is important to inform your healthcare provider about all medications and supplements you are taking.

Can Lorbriqua be taken during pregnancy?

Lorbriqua is not recommended during pregnancy due to potential risks to the fetus. Women should discuss contraceptive options with their healthcare provider while on this medication.